236 related articles for article (PubMed ID: 35787294)
21. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.
Xu YF; Gendron TF; Zhang YJ; Lin WL; D'Alton S; Sheng H; Casey MC; Tong J; Knight J; Yu X; Rademakers R; Boylan K; Hutton M; McGowan E; Dickson DW; Lewis J; Petrucelli L
J Neurosci; 2010 Aug; 30(32):10851-9. PubMed ID: 20702714
[TBL] [Abstract][Full Text] [Related]
22. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.
Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA
Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908
[TBL] [Abstract][Full Text] [Related]
23. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
[TBL] [Abstract][Full Text] [Related]
24. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
25. Early death of ALS-linked CHCHD10-R15L transgenic mice with central nervous system, skeletal muscle, and cardiac pathology.
Ryan ÉB; Yan J; Miller N; Dayanidhi S; Ma YC; Deng HX; Siddique T
iScience; 2021 Feb; 24(2):102061. PubMed ID: 33659869
[TBL] [Abstract][Full Text] [Related]
26. FDA-approved PDE4 inhibitors reduce the dominant toxicity of ALS-FTD-associated
Maitra S; Baek M; Choe YJ; Kim NC
bioRxiv; 2024 Jun; ():. PubMed ID: 38895204
[TBL] [Abstract][Full Text] [Related]
27. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS.
Mitchell JC; Constable R; So E; Vance C; Scotter E; Glover L; Hortobagyi T; Arnold ES; Ling SC; McAlonis M; Da Cruz S; Polymenidou M; Tessarolo L; Cleveland DW; Shaw CE
Acta Neuropathol Commun; 2015 Jun; 3():36. PubMed ID: 26108367
[TBL] [Abstract][Full Text] [Related]
28. Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains.
Janssens J; Philtjens S; Kleinberger G; Van Mossevelde S; van der Zee J; Cacace R; Engelborghs S; Sieben A; Banzhaf-Strathmann J; Dillen L; Merlin C; Cuijt I; Robberecht C; Schmid B; Santens P; Ivanoiu A; Vandenbulcke M; Vandenberghe R; Cras P; De Deyn PP; Martin JJ; Maudsley S; Haass C; Cruts M; Van Broeckhoven C;
Acta Neuropathol Commun; 2015 Nov; 3():68. PubMed ID: 26555887
[TBL] [Abstract][Full Text] [Related]
29. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.
Pirie E; Oh CK; Zhang X; Han X; Cieplak P; Scott HR; Deal AK; Ghatak S; Martinez FJ; Yeo GW; Yates JR; Nakamura T; Lipton SA
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33692125
[TBL] [Abstract][Full Text] [Related]
30. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
[TBL] [Abstract][Full Text] [Related]
31. CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.
Shammas MK; Huang TH; Narendra DP
Biochem Soc Trans; 2023 Apr; 51(2):797-809. PubMed ID: 37021679
[TBL] [Abstract][Full Text] [Related]
32. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
[TBL] [Abstract][Full Text] [Related]
33. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.
Gomez-Deza J; Lee YB; Troakes C; Nolan M; Al-Sarraj S; Gallo JM; Shaw CE
Acta Neuropathol Commun; 2015 Jun; 3():38. PubMed ID: 26108573
[TBL] [Abstract][Full Text] [Related]
34. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
Wegorzewska I; Bell S; Cairns NJ; Miller TM; Baloh RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18809-14. PubMed ID: 19833869
[TBL] [Abstract][Full Text] [Related]
35. Disulfide cross-linked multimers of TDP-43 and spinal motoneuron loss in a TDP-43
Bargsted L; Medinas DB; Martínez Traub F; Rozas P; Muñoz N; Nassif M; Jerez C; Catenaccio A; Court FA; Hetz C; Matus S
Sci Rep; 2017 Oct; 7(1):14266. PubMed ID: 29079747
[TBL] [Abstract][Full Text] [Related]
36. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
37. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
[TBL] [Abstract][Full Text] [Related]
38. Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Kirola L; Mukherjee A; Mutsuddi M
Mol Neurobiol; 2022 Sep; 59(9):5673-5694. PubMed ID: 35768750
[TBL] [Abstract][Full Text] [Related]
39. TDP-43 is a ubiquitylation substrate of the SCF
Rayner SL; Yang S; Farrawell NE; Jagaraj CJ; Cheng F; Davidson JM; Luu L; Redondo AG; Rábano A; Borrego-Hernández D; Atkin JD; Morsch M; Blair IP; Yerbury JJ; Chung R; Lee A
Neurobiol Dis; 2022 Jun; 167():105673. PubMed ID: 35231559
[TBL] [Abstract][Full Text] [Related]
40. C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD.
Ervilha Pereira P; Schuermans N; Meylemans A; LeBlanc P; Versluys L; Copley KE; Rubien JD; Altheimer C; Peetermans M; Debackere E; Vanakker O; Janssens S; Baets J; Verhoeven K; Lammens M; Symoens S; De Paepe B; Barmada SJ; Shorter J; De Bleecker JL; Bogaert E; Dermaut B
Acta Neuropathol; 2023 Jun; 145(6):793-814. PubMed ID: 37000196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]